Work has begun on Zambia’s first cholera vaccine plant, a joint venture between the state-owned Industrial Development Corporation and China’s Jijia International Medical Technology, after a groundbreaking ceremony in Lusaka on 17 November.
The ZAMVAX facility is meant to cut Zambia’s reliance on imported vaccines after a series of deadly cholera outbreaks, and to supply neighbouring markets. China presented it as an outcome of the 2024 Forum on China-Africa Cooperation summit, according to a statement from the Chinese embassy in Zambia.
What will the ZAMVAX cholera vaccine plant do?
Health minister Roma Chilengi said at the ceremony that the plant would strengthen Zambia’s public health system and its capacity to prevent and control infectious diseases, the embassy said. He said it would also serve neighbouring markets and boost Zambia’s regional standing.
Wang Sheng, minister counsellor at the Chinese embassy, described it as the first manufacturing facility in Africa dedicated to cholera vaccines. He said that once complete, the cholera vaccine plant would fill a gap in local production, reduce Zambia’s reliance on imported vaccines and train public health professionals.
The statement did not give the plant’s cost, capacity or completion date. Earlier reports on the project gave some figures. When the two partners signed a memorandum of understanding in October 2024, the first phase was put at $37mn and China pledged to donate 3mn cholera vaccine doses before production began, Africanews reported.
A later joint venture agreement for ZAMVAX Limited put the total investment at about $213mn across two phases, with the IDC holding 60 per cent and Jijia 40 per cent, Lusaka Times reported. The first phase, estimated at $24.13mn, is a fill-and-finish facility for oral cholera vaccine in the Lusaka South Multi-Facility Economic Zone, according to that report. Fill-and-finish plants package vaccine made elsewhere into doses, rather than producing the active ingredient.
Is it Africa’s first cholera vaccine plant?
That depends on the definition. The embassy’s claim that ZAMVAX is Africa’s first facility dedicated to cholera vaccines could not be independently confirmed. South Africa’s Biovac is also developing an oral cholera vaccine: it began a first clinical trial in October 2025 and is building a multi-vaccine plant, due for completion by 2028, that will start with cholera vaccine, Engineering News reported. The African Development Bank lent Biovac $15mn for that plant this year.
Global supply of oral cholera vaccine is tight. For several years almost all doses have come from a single South Korean manufacturer, EuBiologics, and the stockpile managed by international agencies has repeatedly fallen below its emergency target, forcing the use of single-dose rather than two-dose campaigns.
Why does Zambia want its own cholera vaccine plant?
Zambia suffered one of the worst cholera outbreaks in its history in 2023 and 2024, centred on Lusaka, with hundreds of deaths. The government closed schools and turned the national stadium into a treatment centre. Cholera remains a recurring risk across southern and eastern Africa, and outbreaks have spread this year in West and Central Africa too, as UNICEF warned in August, as we reported at the time.
African governments and the Africa CDC have set a target for the continent to make 60 per cent of the vaccines it uses by 2040, up from about 1 per cent. The Chinese embassy said Beijing was ready to work with Zambia to ensure “high-quality construction” of the project and to expand health co-operation.
FAQ
Who owns the ZAMVAX cholera vaccine plant?
It is a joint venture between Zambia’s Industrial Development Corporation and China’s Jijia International Medical Technology. Lusaka Times reported a 60-40 split in the IDC’s favour.
Where is the cholera vaccine plant being built?
Earlier reports placed it in the Lusaka South Multi-Facility Economic Zone.
How much will the plant cost?
The groundbreaking statement gave no figure. Earlier reports put the first phase at $24mn to $37mn and the total project at about $213mn.
Is it Africa’s first cholera vaccine plant?
The Chinese embassy said so, but this could not be independently confirmed. South Africa’s Biovac is also developing a cholera vaccine and building a plant.

